Compare Bath & Body Works Inc (BBWI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs TG Therapeutics Inc — how do they compare? Bath & Body Works Inc trades at $18.16 (market cap $3.81B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BBWI | TGTX | |
|---|---|---|
Market Cap | $3.81B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $59.06 |
52-Week Low | $14.85 | $26.94 |
Enterprise Value | $7.70B | $7.84B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $18.28, down 5.38% over 24 hours, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics with a P/E of 5.36 and P/S of 0.54, while maintaining strong gross margins above 43%. Recent earnings have mostly beaten expectations, and the company is expanding internationally through partnerships with Ulta Beauty and entry into Brazil. Cash flow trends show improvement, with positive net cash flow projected for 2026.
The investment case hinges on BBWI's deep value proposition against declining revenue trends. Key opportunities include international growth and strategic partnerships, while risks involve high debt levels and ongoing revenue pressure. Analyst consensus is mixed with a $22.11 price target suggesting upside potential from current levels.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
